INT14681

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1986
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 31
Total Number 31
Disease Relevance 13.55
Pain Relevance 4.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (GCG) signal transduction (GCG) extracellular space (GCG)
small molecule metabolic process (GCG) extracellular region (GCG) plasma membrane (GCG)
Anatomy Link Frequency
plasma 5
liver 1
lens 1
salivary gland 1
GCG (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatostatin 123 100.00 Very High Very High Very High
Enkephalin 3 100.00 Very High Very High Very High
Cholecystokinin 1 100.00 Very High Very High Very High
anesthesia 9 99.56 Very High Very High Very High
Catecholamine 10 99.00 Very High Very High Very High
tolerance 14 98.84 Very High Very High Very High
substance P 2 98.20 Very High Very High Very High
Neuropeptide 9 96.72 Very High Very High Very High
Bile 12 94.68 High High
addiction 9 93.28 High High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 389 100.00 Very High Very High Very High
Hypoglycemia 161 100.00 Very High Very High Very High
Polycystic Ovary Syndrome 8 100.00 Very High Very High Very High
Gastric Motility Disorder 8 99.32 Very High Very High Very High
Hyperinsulinism 13 99.28 Very High Very High Very High
Impaired Glucose Tolerance 13 99.16 Very High Very High Very High
Malignant Tumors Of Salivary Glands 4 98.90 Very High Very High Very High
Pancreatitis 89 98.68 Very High Very High Very High
Obesity 36 95.88 Very High Very High Very High
Cholestasis 1 95.36 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, an impaired A-cell function may be important, that is characterized by diminished levels of stimulated glucagon.
Negative_regulation (diminished) of glucagon
1) Confidence 0.57 Published 1999 Journal Z Gastroenterol Section Abstract Doc Link 10444809 Disease Relevance 1.06 Pain Relevance 0.46
Glucagon was suppressed in both groups.
Negative_regulation (suppressed) of Glucagon
2) Confidence 0.57 Published 1987 Journal Metab. Clin. Exp. Section Abstract Doc Link 2958673 Disease Relevance 0.48 Pain Relevance 0.26
It is our opinion that the increases of amino acid levels (gluconeogenic and System A amino acids) in patients with pancreatic diabetes is not dependent on maldigestion/malabsorption under treatment, but is mainly dependent on glucagon deficiency.
Negative_regulation (deficiency) of glucagon associated with diabetes mellitus
3) Confidence 0.49 Published 1994 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 7825175 Disease Relevance 0.96 Pain Relevance 0.07
The absence or marked reduction of pancreatic glucagon was confirmed in five of the pancreatectomized patients after intravenous arginine or oral protein.
Negative_regulation (reduction) of glucagon
4) Confidence 0.43 Published 1986 Journal Diabetes Section Abstract Doc Link 3525286 Disease Relevance 0.22 Pain Relevance 0.06
Two patients were also studied before pancreatectomy: suppressibility of glucagon (Mr 3500) was evident.
Negative_regulation (suppressibility) of glucagon
5) Confidence 0.42 Published 1986 Journal Diabetes Section Abstract Doc Link 3525286 Disease Relevance 0.23 Pain Relevance 0.07
Finally, inhibitors of pancreatic secretion including somatostatin, calcitonin and glucagon showed no protective effect for PEP, yet maybe octreotide and beta-carotine administration had a beneficial effect.
Negative_regulation (inhibitors) of glucagon associated with pancreatitis and somatostatin
6) Confidence 0.41 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2921391 Disease Relevance 0.54 Pain Relevance 0.34
Naltrexone treatment did not modify the insulin secretory patterns of control subjects, whereas the same therapy significantly reduced, in hyperinsulinemic PCOs women, the beta-cell hyperresponsiveness both to oral glucose load and to intravenous glucagon (p < 0.05 and p < 0.01, respectively), even if with different mean percent decrease (32% OGTT vs. 45% glucagon, p < 0.05).
Negative_regulation (reduced) of glucagon associated with polycystic ovary syndrome
7) Confidence 0.41 Published 1998 Journal Horm. Res. Section Abstract Doc Link 9623517 Disease Relevance 0.63 Pain Relevance 0.42
In this condition, beta-endorphin produced a significant increase of insulin concentrations, whereas glucagon remained suppressed.
Negative_regulation (suppressed) of glucagon
8) Confidence 0.37 Published 1987 Journal Diabete Metab Section Abstract Doc Link 2896134 Disease Relevance 0.41 Pain Relevance 0.50
Glucose-induced glucagon suppression was significantly lower during beta-endorphin, a fact that could have contributed to the reduced glucose utilization rates.
Negative_regulation (suppression) of glucagon
9) Confidence 0.37 Published 1989 Journal Am. J. Physiol. Section Abstract Doc Link 2551176 Disease Relevance 0.10 Pain Relevance 0
We also measured fasting plasma glucagon and free insulin levels in patients with pancreatic diabetes and in those with primary diabetes.
Negative_regulation (measured) of glucagon in plasma associated with diabetes mellitus
10) Confidence 0.36 Published 1994 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 7825175 Disease Relevance 0.89 Pain Relevance 0.07
It is notable that the increase in glucagon release from the Kir6.2Y12X islets was coincident with increased insulin secretion, reinforcing the view that inhibition of glucagon is not mediated by a factor released by the ?
Negative_regulation (inhibition) of glucagon associated with hyperinsulinism
11) Confidence 0.34 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.10 Pain Relevance 0
It is pertinent that N-type VDCC-deficient mice exhibit reduced serum glucagon levels and improved glucose tolerance despite a parallel reduction in plasma insulin [44].
Negative_regulation (reduced) of glucagon in plasma associated with tolerance and impaired glucose tolerance
12) Confidence 0.33 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.10 Pain Relevance 0.22
-cell regenerative electrical activity underlies glucose-induced suppression of glucagon secretion in man as well.
Negative_regulation (suppression) of glucagon
13) Confidence 0.33 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.05 Pain Relevance 0.24
Through preventing the rapid degradation of incretin hormones, DPP-4 inhibitors result in postprandial increases in levels of biologically active intact GLP-1 and reduce glucose production from the liver by inhibition of glucagon from the ?
Negative_regulation (inhibition) of glucagon in liver
14) Confidence 0.31 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.06 Pain Relevance 0
The postoperative responses of plasma glucagon and insulin were not impaired compared with their preoperative responses.
Negative_regulation (impaired) of plasma glucagon in plasma
15) Confidence 0.31 Published 1987 Journal Jpn J Surg Section Abstract Doc Link 3553685 Disease Relevance 0.37 Pain Relevance 0.14
In diabetic dogs, similar to human diabetics, the glucagon response is abolished and the response of the catecholamines is partially decreased.
Negative_regulation (abolished) of glucagon associated with diabetes mellitus and catecholamine
16) Confidence 0.31 Published 1991 Journal Adv. Exp. Med. Biol. Section Abstract Doc Link 1927681 Disease Relevance 1.16 Pain Relevance 0.36
This effect was associated with a significant reduction of the glucose disappearance rates, suggesting that the inhibition of insulin was of biological relevance. beta-Endorphin also inhibited glucose suppression of glucagon levels and augmented the glucagon response to arginine.
Negative_regulation (suppression) of glucagon
17) Confidence 0.28 Published 1988 Journal Diabetes Section Abstract Doc Link 2970411 Disease Relevance 0.05 Pain Relevance 0.05
Nauck et al (1993) have demonstrated that GLP-1 administration to individuals with type 2 diabetes will facilitate glucose lowering via glucose-dependent stimulation of insulin secretion and suppression of glucagon levels.
Negative_regulation (suppression) of glucagon associated with diabetes mellitus
18) Confidence 0.28 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597758 Disease Relevance 0.63 Pain Relevance 0
Theophylline did not influence significantly the glucagon-releasing effect of beta-endorphin as well as the reduced glucagon suppression.
Negative_regulation (suppression) of glucagon
19) Confidence 0.27 Published 1989 Journal Am. J. Physiol. Section Abstract Doc Link 2551176 Disease Relevance 0.07 Pain Relevance 0.06
The influence of beta-endorphin per se on glucose homeostasis was studied in 7 other subjects using the euglycaemic clamp technique in which the endocrine pancreatic function was fixed at its basal level with somatostatin together with replacement of basal insulin and glucagon by the exogenous infusion of these hormones.
Negative_regulation (replacement) of glucagon associated with somatostatin
20) Confidence 0.26 Published 1987 Journal Acta Endocrinol. Section Abstract Doc Link 2885994 Disease Relevance 0 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox